* types
** HIV-1
- fast transmission
- found everywhere
** HIV-2
- Mostly found in West Africa
- Slow rate of transmission & progression
- Many subtypes (strains)
* AIDS
** diagnosis
- OR
  - OR
    - HIV-(+) with a CD4 count currently
    - has ever had <200 cells/mm^3
  - AND
    - HIV-(+)
    - currently or has ever had an AIDS-defining illness
** AIDS-defining illnesses
- toxoplasmosis
- MAC
- Kaposi’s sarcoma
- PCP
* diagnosis
** TODO [#A] OTC :l:
*** Home Access Express HIV-1 Test System
- fingerstick blood sample
- requires shipping
- results next business day
- disadvantages
  - time
  - needles
*** [#B] OraQuick In-Home HIV test
- oral swab
- results in 20-40 minutes
- after 40 minutes, test is invalid; must be read
- disadvantages
  - harder to read
** labs :l:
*** genotype
**** mutations
***** [#A] M184V
good---causes virus to replicate slower
****** drugs resistant
- emtricitabine
- lamivudine
****** hypersusceptible
- stavudine
- zidovudine
- tenofovir
***** [#A] K103
bad---causes drug resistance
****** drugs resistant
- nevirapine
- efavirenz
- delaviridine
*** HLA-B*5701
*** trofile testing
** CD4 count
** viral load
*** definition
amount of HIV RNA in blood
*** [#B] goal
- VL as low as possible; <20 or <50
- CD4 count as high as possible
* resistance
** types :l:
*** treatment-emergent; adherence
suboptimal antiretroviral therapy
*** transmitted
transmission of a resistant virus
* [#A] HIV replication cycle :l:
** 1. binding/attachment
*** drugs that target
- CCR5 antagonist
- monoclonal antibodies
** 2. fusion
*** drugs that target
fusion inhibitors
** 3. reverse transcription
*** drugs that target
- NRTIs
- NNRTIs
** 4. integration
*** drugs that target
INSTIs
** 5. replication
** 6. assembly
** 7. budding and maturation
*** drugs that target
PIs
* drug classes
** TODO brand and generics
** TODO individual agents of coformulations
** TODO distinguish complete vs. incomplete antiretroviral regimens
** TODO for each antiretroviral agent...
- [ ] black box warning
- [ ] contraindication
- [ ] most common side effects
- [ ] significant drug-drug interactions
- [ ] significant drug-food itneractions
** Nucleo[st]ide Reverese Transcriptase Inhibitors (NRTIs) (“the nukes”)
*** by nucleic acid derivative
**** adenosine derivatives :l:
***** didanosine
****** brand
Videx EC
***** tenofovir
****** salts :l:
******* tenofovir disoproxil fumarate (TDF)
******** brand
Viread
******** [#B] activity
activity against HBV
******** [#B] adverse effects
- Fanconi’s syndrome; renal insufficiency
- bone density loss
  - osteomalacia
  - osteoporosis
******** dose adjustment 
CrCl < 15
******* tenofovir alafenamide fumarate (TAF)
******** brand
Vemlidy
****** [#B] comparison between TAF and TDF
- TAF is generally better because it is more well-tolerated with less side effects
  - bone loss
  - renal insufficiency
**** cytosine derivatives :l:
***** emitricitabine
****** brand
Emtriva
****** resistance
presence of M184V genotype
****** adverse effects
hyperpigmentation
***** lamivudine
****** brand
Epivir
****** dosing
- 150 mg BID
- 300 mg daily
- no food restrictions
****** activity
- has activity against hepatitis B
- Epivir-HBV 100mg tab is for HBV only
****** adverse drug reactions
very well tolerated
**** thymidine derivatives :l:
***** stavudine
****** brand
Zerit
***** zidovudine
****** brand
Retrovir
****** [#B] black box warning
- hematologic toxicities
- myopathy/myositis with prolonged use
****** adverse drug reactions
- skin/nail hyperpigmentation
- nausea/vomiting
****** [#B] indication
only for pregnant women giving birth---literally during labor
**** guanine derivatives :l:
***** abacavir
****** [#A] black box warning
fatal hypersensitivity
****** dose adjustment
- no renal
- hepatic dosing for Child Pugh A ⇒ 200 mg BID
****** food requirement
none
****** brand
Ziagen
****** hypersensitivity
******* [#B] test
- HLA-B*5701 required prior to initiating therapy
- if positive, do not use abacavir
******* [#B] symptoms
- fever
- rash
- GI symptoms
- general illness, fatigue, achy
- SOB, cough, or sore throat
*** combinations
**** dose adjustment
- do not use combination products CrCl <50 ml/min
- except Descovy with CrCl ≥ 30 mL/min
**** clean :l:
***** tenofovir alafenamide /emtricitabine
****** brand
Descovy
****** unique
this is new
****** dosing
- 200 mg emtricitabine / 25 mg tenofovir alafenamide daily
- no food restrictions
****** indication
Hep B
***** tenofovir disoproxil / emtricitabine
****** [#A] brand
Truvada
****** [#B] indications
Pre-Exposure Prophylaxis (PrEP); only drug approved for this
****** dose
300 mg tenofovir disoproxil fumarate / 200 mg emtricabine
****** requirements
- CrCl > 70 mL/min to start
- if CrCl falls below 50, switch
- if CrCl falls below 70, monitor
***** abacavir / lamivudine
****** brand
Epzicom
****** dose
600 mg abacavir / 300 mg lamivudine
****** requirements
patients must be HLA-B*5701 negative
***** lamivudine / tenofovir disoproxil
****** brand
Cimduo
****** requirements
CrCl ≥ 70 mL/min
**** TODO dirty dogs :l:
*** adverse drug reactions
GI related
*** dose adjustments
renal dose adjustment; for all except abacavir
** Integrase Inhibitors
*** common suffix
-tegravir
*** mnemonics
BRED
- Bictegravir
- Raltegravir
- Elvitegravir
- Dolutegravir
*** drugs
**** single agents :l:
***** bictegravir
***** raltegravir
***** TODO elvitegravir
****** food requirement
requires food
***** dolutegravir
****** [#B] brand
Tivicay
****** [#B] drug interactions
- metformin; max dose is 250 mg; decrease by .25x
- rifampin
****** TODO 3A4 dosing
**** combinations :l:
***** Bictegravir / tenofovir alafenamide / emtricitabine
****** [#B] brand
Biktarvy
****** [#B] formulation
single tablet regimen
****** TODO pluses vs slashes in the generic names
***** Raltegravir
****** [#B] brand
Isentress
****** [#B] indication
post-exposure prophylaxis (PEP) in combination with tenofovir disoproxil / emtricitabine (Truvada)
****** food requirements
none
*** food requirements
only elvitegravir needs to be taken with food
*** [#A] drug interactions
**** in general
many interactions with antacids and polyvalent cations
**** TODO memorize slide 172
** Non-Nucleotide Reverse Transcriptase Inhibitors (NNRTIs)
*** single agents :l:
**** Nevirapine
***** brand
Viramune®
**** Evavirenz
***** brand
Sustiva®
***** warnings
- pregnancy category D---causes neural tube defects
- false positive cannabinoid or benzodiazepine drug test results
***** pharmacokinetics
- strong CYP3A4 inducer
- moderate 2C9/19 inhibitor
***** adverse effects
- CNS side effects
- hypertriglyceridemia
***** counseling
take on an empty stomach
**** Delaviridine
***** brand
Rescriptor®
**** Etravirine
***** brand
Intelence®
**** Rilpivirine
***** brand
Edurant®
***** contraindications
- PPIs
- strong 3A4 inducers; i.e., rifampin
*** combinations :l:
**** Efavirenz / emtricitabine / tenofovir disoproxil
***** brand
Atripla®
**** Rilpivirine / emtricitabine / tenofovir disoproxil
***** brand
Complera®
**** Rilpivirine / emtricitabine / tenofovir alafenamide
***** brand
Odefsey®
**** Rilpivirine / dolutegravir
***** brand
Juluca®
***** components
- 50 mg dolutegravir
- 25 mg rilpivirine
***** requirements
+ CrCl ≥ 30 mL/min
+ AND
  - virologically suppressed on stable antiretroviral regimen for ≥ 6 months
  - no history of treatment failure
  - no resistance to dolutegravir or rilpivirine
***** formulation
single tablet regimen
***** pharmacokinetics
****** coadministration with rifambutin
**** Efavirenz/Lamivudine/ Tenofovir disoproxil fumarate
***** brand
Symfi®
**** Doravirine / lamivudine / tenofovir disoproxil
***** brand
Delstrigo®
** Fusion Inhibitors :l:
*** Enfuvirtide
**** brand
Fuzeon®
**** usage
salvage therapy
** CCR5 antagonists
*** indication
acute early infections
*** requirements
trophism assay returning CCR5 result
*** agents :l:
**** Maraviroc
***** brand
Selzentry
***** indications
- HIV-1
- CCR5-tropic viral infections
***** black box warning
hepatotixicity preceded by systemic allergic rash with eosinophilia
** Protease Inhibitors
*** drugs
**** single agents :l:
***** Atazanavir
****** brand
Reyataz®
***** Darunavir
****** brand
Prezista®
***** Lopinavir/ritonavir
****** brand
Kaletra®
***** Fosamprenavir
****** brand
Lexiva®
***** Saquinavir
****** brand
Invirase®
***** Nelfinavir
****** brand
Viracept®
***** Indinavir
****** brand
Crixivan®
***** Tipranavir
****** brand
Aptivus®
**** combinations :l:
***** Darunavir / cobicistat
****** brand
Prezcobix®
***** Atazanavir / cobicistat
****** brand
Evotaz®
***** Lopinavir / ritonavir
****** brand
Kaletra®
***** Darunavir / cobicistat / emtricitabine / TAF
****** brand
Symtuza®
*** therapeutics
**** preferred agents
- atazanavir
- darunavir
**** adverse effects
- lipodystrophy
- metabolic
  - insulin resistance
  - lipid abnormalities
- LFT elevations
** Monoclonal Antibody
*** Ibalizumab-uiyk
**** brand
Trogarzo®
**** [#B] dosing
***** initial
2,000 mg into a 250 mL bag of NS infused as a single dose over >30 mins
***** maintenance
800 mg into a 250 mL bag of NS infused over >15 mins then observe >15 mins
***** [#A] missed maintenance dose
If missed maintenance dose by >3 days past originally scheduled day, must re-do initial dose
* therapeutics
** NRTIs
*** [#A] combination treatments
do not pick 2 derivatives of the same nucleic acid
*** which to use
*** [#A] thymidine derivatives
do not use except in pregnancy
*** clean vs. dirty
**** [#B] clean
- tenofovir disoproxil
- tenofovir alafenamide
- emtricabine
- abacavir
- lamivudine
**** dirty
- stavudine
- didanosine
- zidovudine
*** black box warning
- hepatomegaly with steatosis
- lactic acidosis
** treatment-naive patient
*** [#A] never use
- nevirapine
- efavirenz
- delaviridine
*** initial regimens :l:
**** Bictegravir / tenofovir alafenamide / emtricitabine
***** brand
Biktarvy®
**** Dolutegravir / abacavir / lamivudine
***** brand
Triumeq®
**** Dolutegravir + tenofovir alafenamide / emtricitabine
***** brand
Tivicay® + Descovy®
**** Dolutegravir + tenofovir disoproxil / emtricitabine
***** brand
Tivicay® + Truvada®
**** Raltegravir + tenofovir alafenamide / emtricitabine
***** brand
Isentress® + Descovy®
**** Raltegravir + tenofovir disoproxil / emtricitabine
***** brand
Isentress® + Truvada®
**  [#A] treatment-naive pregnant patient
- BOTH
  + 2 NRTIs
    + abacavir/lamivudine
    + emtricitabine/ tenofovir disoproxil fumarate
    + lamivudine/ tenofovir disoproxil fumarate
  + OR
    + boosted PI
      + darunavir/ritonavir
      + atazanavir/ritonavir
    + INSTI: raltegravir
** [#A] perinatal prophylaxis
zidovudine during intrapartum
** coinfection with hepatitis B
*** mnemonic
LET it B
L = Lamivudine
E = Emtricitabine
T = Tenofovir disoproxil fumarate or Tenofovir alafenamide
B = Hepatitis B
*** potency
1. Entecavir 
2. Tenofovir 
3. Lamivudine 
4. Adefovir 
5. Emtricitabine
** TODO prophylaxis
*** types
**** PEP
**** NPEP
*** drugs
- raltegravir
- Truvada
* opportunistic infections in HIV
** CD4 count correlations
*** ≤ 200
- candidiasis
- Pneumocystis jirovecii pneumonia
*** ≤ 100
- Toxoplasmosis
- Cytomegalovirus
- Cryptococcus
*** ≤ 50
Mycobacterium avium complex
** infections
*** Candidiasis
**** oropharyngeal
***** [#A] treatment
fluconazole 100 mg PO daily x7-14d
***** CD4
≤ 200 cells/mm^3
**** esophageal
***** risk factors
- CD4 <100 cells/mm^3
- oropharyngeal candidiasis
***** treatment
****** [#A] preferred
- /Fluconazole 100 mg (up to 400 mg) PO/IV daily x 14–21 days/
- Itraconazole solution 200 mg PO daily x 14–21 days
****** time to resolution
48-72 hours
*** Pneumocystis jirovecii pneumonia (PCP)
**** etiology
- 2nd most common opportunistic infection in HIV-(+) patients
- accounts for a lot of initial AIDS diagnoses
**** therapeutics
***** primary prophylaxis
****** [#B] CD4 cutoff
≤ 200 cells/mm^3
****** indications
- OR
  - CD4 <200
  - CD4 <14%
  - CD4 (200, 250) if antitretroviral therapy must be delayed
***** secondary prophylaxis
****** indication
- AND
  - history of PCP
  - CD4 <200
****** discontinue when
CD4 >200 for ≥ 3 months with antiretrovirals
**** treatment
***** prophylaxis
****** hierarchy
1. TMP/SMX
2. Dapsone
3. Dapsone + Pyrimethamine + Leucovorin
4. Aerosolized pentamidine
5. Atovaquone
****** preferred
TMP/SMX
****** drugs :l:
******* TMP/SMX
******** brand
- Bactrim
- Septra
******** dose
1 DS tab PO daily
******** adverse effects
photosensitivity
******* Dapsone
******** indication
Bactrim or sulfa allergy
******** [#A] requirement
G6PD deficiency test
******** [#B] G6PD test
- glucose-6-dehydrogenase test
- if deficient, don’t administer...
  - primaquine
  - dapsone
******* Dapsone + Pyrimethamine + Leucovorin
******* pentamidine (aerosolized)
******** brand
Pentam
******* Atovaquone
******** brand
Mepron
***** treatment
****** mild to moderate
******* formulation
PO
******* drugs :l:
******** TMP/SMX
********* [#B] dose
- TMP: 15–20 mg/kg/d in 3 to 4 divided doses (q 6 – 8h) x 21 days
- SMX: 75–100 mg/kg/d in 3 to 4 divided doses (q 6 – 8h) x 21 days
******** TMP/Dapsone
******** Clindamycin/Primaquine
********* requirement
G6PD test for deficiency
******** Atovaquone
****** moderate to severe
******* formulation
IV
******* drugs :l:
******** TMP/SMX (IV)
******** Pentamidine (IV)
********* contraindications
cardiovascular issues
******** corticosteroid adjuvant treatment
********* [#A] dose
********** conversion
5:4 prednisone (PO) : methylprednisone (IV)
********** 21-day prednisone treatment
- Days 1 – 5: 40 mg PO twice daily
- Days 6 – 10: 40 mg PO daily
- Days 11 – 21: 20 mg PO daily
********* indications
- PaO2 <70 mm Hg

*** Cryptococcosis
**** prophylaxis
***** secondary
**** treatment
***** [#A] preferred
- Amphotericin B 3–4 mg/kg IV daily + Flucytosine 25 mg/kg PO QID x 2 weeks
- THEN Fluconazole 400 mg PO/IV daily x 8 weeks
- THEN Fluconazole 200 mg PO bid x 1 year
*** Cytomegalovirus (CMV)
**** treatment
***** preferred
****** drugs
- ganciclovir (IV)
- valganciclovir (PO)
****** [#B] frequency/schedule
- induction period: BID x14-21d
- maintenance daily
*** Toxoplasmosis
**** CD4
<100
**** therapeutics
***** prophylaxis
****** primary
+ AND
  + CD4 <100 cells/mm3
  + Toxoplasma IgG-(+)
****** conditions to stop or restart
- May d/c when CD4 >200 cells/mm3 for >3 months
- Restart if CD4 <100 to 200 cells/mm3
**** treatment
***** preferred
****** strategy
3 agents for 6 weeks
****** [#A] weight <60 kg
+ Pyrimethamine 200 mg PO LD, THEN 50 mg PO daily
+ Sulfadiazine 1000 mg PO QID
+ Leucovorin 10–25 mg PO daily
****** [#A] weight >60 kg
+ Pyrimethamine 200 mg PO LD, THEN 75 mg PO daily
+ Sulfadiazine 1500 mg PO QID
+ Leucovorin 10–25 mg PO daily
**** leucovorin
***** [#A] rationale
prevent drug-induced myelopsuppression from pyrimethamine
*** Mycobacterium avium complex (MAC)
